Physician profile
Mark Jaffe
NPI 1730160615
$17,732.53
in general payments reported to CMS, 2019-2025
41 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,347 · 2020: $1,738 · 2021: $2,881 · 2022: $2,859 · 2023: $1,999 · 2024: $2,657 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,098 · Consulting Fee: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,097.51 |
| Consulting Fee | $810.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $5,379.78 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $3,888.10 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Horizon Therapeutics Plc | $3,200.15 | 2019-2023 | Krystexxa |
| Abbvie INC. | $1,642.07 | 2019-2025 | |
| Pfizer INC. | $666.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $433.29 | 2021-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $370.83 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $289.91 | 2020-2025 | Acthar |
| Lilly USA, LLC | $231.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $221.47 | 2019-2025 | |
| Ucb, INC. | $193.51 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $140.43 | 2019-2024 | Benlysta |
| Ani Pharmaceuticals, INC. | $139.35 | 2023-2024 | Purified Cortrophin Gel |
| Mitsubishi Tanabe Pharma Development America, INC. | $134.14 | 2022 | |
| Sobi, INC | $120.11 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $94.29 | 2021-2022 | |
| Sandoz INC. | $82.85 | 2023-2025 | Hyrimoz |
| Genentech USA, INC. | $66.71 | 2019-2023 | Actemra |
| Radius Health, INC. | $55.15 | 2019-2020 | |
| Genentech, INC. | $50.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.98 | 2020-2023 | Cyltezo |
| Celgene Corporation | $44.69 | 2019 | |
| Depuy Synthes Sales INC. | $34.44 | 2024 | Orthovisc |
| Octapharma USA, INC. | $30.38 | 2022 | |
| Mallinckrodt Enterprises LLC | $25.17 | 2019 | |
| Genzyme Corporation | $24.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.67 | 2020 | |
| Kyowa Kirin, INC. | $20.46 | 2023 | Crysvita |
| Alvogen INC | $19.31 | 2024 | Teriparatide |
| Collegium Pharmaceutical, INC. | $18.64 | 2019 | |
| Eisai INC. | $15.65 | 2021 | |
| Avion Pharmaceuticals | $14.16 | 2020 | |
| Janssen Scientific Affairs, LLC | $13.89 | 2024 | Tremfya |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.